Athira Pharma (NASDAQ:ATHA) Announces Earnings Results, Misses Estimates By $1.51 EPS

Athira Pharma (NASDAQ:ATHA) announced its quarterly earnings data on Thursday. The company reported ($1.68) EPS for the quarter, missing the consensus estimate of ($0.17) by ($1.51), Zacks reports.

Athira Pharma Price Performance

NASDAQ ATHA traded down $0.16 during midday trading on Friday, hitting $3.85. 43,504 shares of the company traded hands, compared to its average volume of 27,304. Athira Pharma has a 52 week low of $2.20 and a 52 week high of $8.26. The company’s 50-day simple moving average is $3.96 and its 200-day simple moving average is $3.59. The company has a market cap of $15.17 million, a PE ratio of -0.40 and a beta of 3.04.

Analyst Ratings Changes

Several research firms have recently weighed in on ATHA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Athira Pharma in a research report on Wednesday, October 8th. Mizuho set a $4.00 price objective on shares of Athira Pharma in a report on Friday, September 19th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell” and a consensus price target of $4.00.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.